

Fig. 1. Mean (\pm SD) darunavir (DRV) trough concentration (left panel) and area under the time–concentration curve (AUC)₀₋₂₄ (right panel) measured in patients given DRV with or without concomitant raltegravir (RAL) administration.

drug exposure. Moreover, recent studies have demonstrated that RAL has a resistance time on the integrase/DNA pre-integration complex that exceeds the half-life of the pre-integration complex in the cells [4,5]. Consequently, as the inhibition induced by RAL is functionally irreversible, no association between RAL pharmacokinetics and clinical outcome can be reasonably expected [6]. According to these findings, it is unlikely that RAL trough concentrations can *per se* directly affect response to therapy of patients enrolled in the ACTG trial. Therefore, other ways in which RAL could indirectly impact on patient outcome should be advocated.

A clear indication from the ACTG trial is that, according to sensitivity analyses, DRV concentrations were significantly lower in patients with virologic failure compared with those without virologic failure. Therefore, any factor able to affect DRV pharmacokinetics could theoretically impact on patient outcome. An intriguing hypothesis is that co-administration of RAL may lower plasma concentrations of DRV, as recently documented by Fabbiani *et al.* [7], ultimately resulting in suboptimal DRV exposure and poor response to combined RAL and DRV therapy. Unfortunately, no matched control patients given DRV/r at comparable dosage without RAL were available from the ACTG trial to compare DRV plasma trough concentrations in patients given or not given RAL. The authors have, however, rejected the hypothesis of a drug–drug interaction because the DRV trough concentrations measured in the ACTG trial were ‘within the range previously reported in an intensive pharmacokinetic study of DRV 800/100 mg daily’ [8]. Taiwo *et al.* [1] failed, however, to consider an important methodological drawback of their study. Particularly, they based their assumptions on the assessment of trough DRV

concentration as the solely pharmacokinetic drug parameter, which is not appropriate for the assessment of drug–drug interactions. Indeed, by performing detailed DRV pharmacokinetic evaluations in 25 HIV-infected patients [9], we have recently shown that co-administration of RAL did not impact on DRV trough levels, but was associated with highly significantly lower DRV AUC₀₋₂₄ compared with values measured in patients not given RAL (Fig. 1).

According to these findings, a potential pharmacokinetic drug–drug interaction between RAL and DRV ultimately affecting the results of the ACTG A5262 trial cannot be ruled out. This potential interaction should be investigated further and taken into account when DRV with RAL-based HAART regimens are implemented in the setting of HIV.

Acknowledgements

Both authors have read and approved the text.

Conflicts of interest

D.C. has received educational/travel grants from Merck Sharp & Dome (MSD) and from Janssen-Cilag.

C.G. has received educational grants from Merck Sharp & Dome (MSD), Janssen-Cilag, Bristol Myers Squibb and Abbott.

Cristina Gervasoni^a and Dario Cattaneo^b, ^aThird Division of Infectious Diseases, and ^bUnit of Clinical Pharmacology, Luigi Sacco University Hospital, Università di Milano, Milan, Italy.

Correspondence to Cristina Gervasoni, MD, Third Division of Infectious Diseases, Luigi Sacco University Hospital, via GB Grassi 74, 20157 Milan, Italy.
E-mail: cristina.gervasoni@unimi.it

Received: 16 September 2011; accepted: 25 October 2011.

References

- Taiwo B, Zheng L, Gallien S, Matining RM, Kuritzkes DR, Wilson CC, et al. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naïve HIV-1-infected patients (ACTG A5262). *AIDS* 2011; 25:2113–2122.
- Cattaneo D, Ripamonti D, Gervasoni C, Landonio S, Meraviglia P, Baldelli S, et al. Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-infected patients. *J Clin Pharmacol* 2011 [Epub ahead of print].
- Burger D, Colbers EPH, van Luin M, Koopmans PP. AUC0-3 h of raltegravir is correlated to AUC0-12 h: a novel approach for therapeutic drug monitoring of raltegravir [abstract 41]. In: 11th International Workshop on Clinical Pharmacology of HIV Therapy; 7–9 April 2010; Sorrento, Italy.
- Grobler JA, McKenna PM, Ly S. Functionally irreversible inhibition of integration by slowly dissociating strand transfer inhibitor [abstract O-10]. In: 10th International Workshop on Clinical Pharmacology of HIV Therapy; 15–17 April 2009; Amsterdam, the Netherlands.
- McSharry J, Weng Q, Zager K, Soldani K, Kulawy R, Drusano G. Pharmacodynamics of raltegravir, an HIV integrase inhibitor in an in vitro hollow fiber infection model system [abstract A-960]. In: ICAAC/IDSA; October 2008; Washington, District of Columbia, USA.
- Brainard DM, Wenning LA, Stone JA, Wagner JA, Iwamoto M. Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor. *J Clin Pharmacol* 2011; 51:1376–1402.
- Fabbiani M, Di Giambenedetto S, Ragazzoni E, D’Ettore G, Parruti G, Prosperi M, et al. Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction. *Pharmacol Res* 2011; 63:249–253.
- Boffito M, Moyle M, Hill A, Sekar V, Lefebvre E, De Pauw M. The pharmacokinetic profile of darunavir with low-dose ritonavir (DRV/r) in various multiple-dose regimens over 120 h [abstract P-31]. In: 9th International Workshop on Clinical Pharmacology of HIV Therapy; 7–9 April 2008; New Orleans, Louisiana, USA.
- Cattaneo D, Gervasoni C, Cozzi V, Baldelli S, Fucile S, Meraviglia P, et al. Influence of raltegravir on the pharmacokinetics of darunavir in HIV-1-infected patients. *Pharmacol Res* 2011 [Epub ahead of print].

DOI:10.1097/QAD.0b013e32834e9d9e

Epstein–Barr virus associated colitis in an HIV-infected patient

Epstein–Barr virus (EBV)-associated lymphoma of the gastrointestinal tract is common in HIV-infected patients [1]. However, EBV involvement of the gastrointestinal tract without frank lymphoma is rare [2]. Although a few cases of EBV-associated colitis in both immunocompetent and immunocompromised patients have been reported [2,3], to our knowledge, EBV-associated colitis in HIV-infected patients has never been reported. We report a case of EBV-associated colitis with HIV infection successfully treated by combination antiretroviral therapy (cART).

A 40-year-old homosexual man who had had diarrhea for a few years developed bloody diarrhea. After persistence of the symptom for 2 months, he sought medical advice at a local hospital. He was diagnosed with HIV infection and referred to our hospital for further examination. On admission, the patient was alert with body temperature of 37.6°C. Physical examination showed oral candidiasis but no peripheral lymphadenopathy or abdominal tenderness. Laboratory tests at admission showed low CD4⁺ cell count (84 cells/μl), anemia (hemoglobin 10.6 g/dl), low serum albumin (2.1 g/dl), and elevated C-reactive protein (3.45 mg/dl). Colonoscopy showed diffuse edematous mucosa with deep ulcers in the rectum, sigmoid colon, and descending colon (Fig. 1a), suggestive of either cytomegalovirus (CMV) colitis or amebic colitis. Based on the clinical suspicion, we initiated empirical treatment of ganciclovir and metronidazole. However, the results for amebic colitis such as stool microscopy, serum antiamebic antibody, and trophozoites in colonic biopsy specimens were all negative. Furthermore, histopathol-

ogy revealed no inclusion bodies and negative immunological staining for CMV. Then, we suspected inflammatory bowel disease (IBD), and mesalazine 4 g/day was initiated on day 7. Since there was no sign of other opportunistic infections, cART of raltegravir and emtricitabine/tenofovir was initiated on day 13. However, the bloody diarrhea persisted and a repeat colonoscopy was performed on day 19 to investigate the cause. The edematous mucosa and deep ulcers were still observed on colonoscopy. To identify infectious agents, a polymerase chain reaction (PCR) assay for EBV in the biopsy sample was performed, which showed 9000 copies/ml. Histopathological examination showed dense lymphoplasmacytic infiltration and mild neutrophil infiltration (Fig. 1c). In-situ hybridization (ISH) for EBV-encoded small RNA-1 (EBER-1) showed some positive cells (Fig. 1d). Based on these tests, the final diagnosis was established as EBV-associated colitis. The treatment plan included continuation of cART and withdrawal of mesalazine since IBD was considered unlikely. The symptom of bloody diarrhea gradually improved and disappeared by cART alone. At 3 months, the CD4 cell count had increased to 190/μl and the third colonoscopy showed significant improvement (Fig. 1b). PCR for EBV DNA in the biopsy sample showed a decrease to 80 copies/ml, and ISH showed no EBER-1-positive cells.

Although EBV-associated lymphoma of the gastrointestinal tract is common, EBV-associated colitis is very rare. To our knowledge, this is the first study demonstrating EBV-associated colitis in an HIV-infected patient. In




Fig. 1. Endoscopic and microscopic findings. Colonoscopic findings (a) on admission and (b) on 105th day of antiretroviral therapy. (c) Histopathological examination showing granulation tissue in ulcer floor (hematoxylin-eosin staining). (d) Epstein–Barr virus-encoded small RNA-1 in-situ hybridization demonstrated the presence of positive cells (black arrow).

In addition, the significant improvement was achieved by cART alone. Several cases of EBV-associated colitis have been reported previously in immunocompromised patients, such as post-transplant patients and patients with IBD treated with immunosuppressants [2,3]. For this reason, EBV reactivation due to impaired immunity is considered to be a major causative factor of EBV-associated colitis.

In this case, EBV-associated colitis was diagnosed by the presence of EBV DNA and EBER-1-positive cells in the biopsy sample, and the improvement of colonoscopic findings associated with a decrease in EBV DNA. Because colonic appearance is grossly indistinguishable from that of CMV colitis, other forms of infectious colitis and IBD, positive EBV DNA and EBER-1 in the colonic specimens are important findings for establishing the correct diagnosis. In the case of delayed recognition of EBV colitis, treatment for IBD with corticosteroids can lead to unfavorable outcome [4]. Thus, EBV-associated colitis should be considered in HIV-infected patients, especially those with low CD4⁺ cell counts, who present with colitis of unclear cause.

Because there is no established treatment for EBV infection, we treated this case with cART alone without specific treatment for EBV [5]. The loss of CMV viremia by cART in the absence of specific anti-CMV therapy has been reported previously [6]; therefore, it is likely that the suppression of EBV was also achieved by cART alone.

Because most reported cases of EBV colitis occurred from EBV reactivation due to impaired immunity, it is rational that restoration of the immune system by cART allowed the suppression of EBV activation and resulted in the resolution of colitis.

In conclusion, cART was effective against EBV-associated colitis. Clinicians should consider EBV infection in HIV-infected patients who present with colitis of unclear cause.

Acknowledgements

The authors thank all the clinical staff at the AIDS Clinical Center and also all the staff of the endoscopy unit.

All of the authors contributed to the concept, design, and writing of this submission. No financial support was received for this article.

Conflicts of interest

There are no conflicts of interest.

Yohei Hamada^a, Naoyoshi Nagata^b, Haruhito Honda^a, Naoki Asayama^b, Katsuji Teruya^a, Toru Igari^c, Yoshimi Kikuchi^a and Shinichi Oka^a, ^aAIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, ^bDepartment of Gastroenterology and Hepatology, and ^cDepartment of Pathology, Division of Clinical Laboratory, National Center for Global Health and Medicine, Tokyo, Japan.

Correspondence to Naoyoshi Nagata, MD, Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo 162-8655, Japan. Tel: +81 3 3202 7181; fax: +81 3 3208 4244; e-mail: nnagata_ncgm@yahoo.co.jp

Received: 14 November 2011; accepted: 15 November 2011.

References

1. Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF. **HIV-associated lymphomas and gamma-herpesviruses.** *Blood* 2009; **113**:1213–1224.
2. Karlitz JJ, Li ST, Holman RP, Rice MC. **EBV-associated colitis mimicking IBD in an immunocompetent individual.** *Nat Rev Gastroenterol Hepatol* 2011; **8**:50–54.
3. Tashiro Y, Goto M, Takemoto Y, Sato E, Shirahama H, Utsunomiya A, et al. **Epstein-Barr virus-associated enteritis with multiple ulcers after stem cell transplantation: first histologically confirmed case.** *Pathol Int* 2006; **56**:530–537.
4. Kobayashi CI, Yamamoto G, Hayashi A, Ota S, Imai Y, Fukayama M, et al. **Fatal amebic colitis after high-dose dexamethasone therapy for newly diagnosed multiple myeloma.** *Ann Hematol* 2011; **90**:225–226.
5. Torre D, Tambini R. **Acyclovir for treatment of infectious mononucleosis: a meta-analysis.** *Scand J Infect Dis* 1999; **31**:543–547.
6. Deayton J, Mocroft A, Wilson P, Emery VC, Johnson MA, Griffiths PD. **Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy.** *AIDS* 1999; **13**:1203–1206.

DOI:10.1097/QAD.0b013e32834f411b

Renal Function Declines More in Tenofovir- than Abacavir-Based Antiretroviral Therapy in Low-Body Weight Treatment-Naïve Patients with HIV Infection

Takeshi Nishijima^{1,4}, Hiroyuki Gatanaga^{1,4*}, Hirokazu Komatsu³, Kunihisa Tsukada¹, Takuro Shimbo², Takahiro Aoki¹, Koji Watanabe^{1,4}, Ei Kinai¹, Haruhito Honda¹, Junko Tanuma¹, Hirohisa Yazaki¹, Miwako Honda¹, Katsuji Teruya¹, Yoshimi Kikuchi¹, Shinichi Oka^{1,4}

1 AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan, **2** Department of Clinical Research and Informatics, International Clinical Research Center, National Center for Global Health and Medicine, Tokyo, Japan, **3** Department of Community Care, Saku Central Hospital, Nagano, Japan, **4** Center for AIDS Research, Kumamoto University, Kumamoto, Japan

Abstract

Objective: To compare the rate of decline of renal function in tenofovir- and abacavir-based antiretroviral therapy (ART) in low-body weight treatment-naïve patients with HIV infection.

Design: We conducted a single-center retrospective cohort study of 503 Japanese patients who commenced on either tenofovir- or abacavir-based initial ART.

Methods: The incidence of renal dysfunction, defined as more than 25% fall in estimated glomerular filtration rate (eGFR) from the baseline, was determined in each group. The effect of tenofovir on renal dysfunction was estimated by univariate and multivariate Cox hazards models as the primary exposure. Changes in eGFR until 96 weeks were estimated in both groups with a repeated measures mixed model.

Results: The median body weight of the cohort was 64 kg. The estimated incidence of renal dysfunction in the tenofovir and the abacavir arm was 9.84 per 100 and 4.55 per 100 person-years, respectively. Tenofovir was significantly associated with renal dysfunction by univariate and multivariate analysis (HR=1.747; 95% CI, 1.152–2.648; p=0.009) (adjusted HR=2.080; 95% CI, 1.339–3.232; p<0.001). In subgroup analysis of the patients stratified by intertertile baseline body weight, the effect of tenofovir on renal dysfunction was more evident in patients with lower baseline body weight by multivariate analysis (≤ 60 kg: adjusted HR=2.771; 95%CI, 1.494–5.139; p=0.001) (61–68 kg: adjusted HR=1.908; 95%CI, 0.764–4.768; p=0.167) (>68 kg: adjusted HR=0.997; 95%CI, 0.318–3.121; p=0.995). The fall in eGFR was significantly greater in the tenofovir arm than the abacavir arm after starting ART (p=0.003).

Conclusion: The incidence of renal dysfunction in low body weight patients treated with tenofovir was twice as high as those treated with abacavir. Close monitoring of renal function is recommended for patients with small body weight especially those with baseline body weight <60 kg treated with tenofovir.

Citation: Nishijima T, Gatanaga H, Komatsu H, Tsukada K, Shimbo T, et al. (2012) Renal Function Declines More in Tenofovir- than Abacavir-Based Antiretroviral Therapy in Low-Body Weight Treatment-Naïve Patients with HIV Infection. PLoS ONE 7(1): e29977. doi:10.1371/journal.pone.0029977

Editor: Claire Thorne, UCL Institute of Child Health, University College London, United States of America

Received: September 21, 2011; **Accepted:** December 7, 2011; **Published:** January 5, 2012

Copyright: © 2012 Nishijima et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by a Grant-in Aid for AIDS research from the Japanese Ministry of Health, Labour, and Welfare (H20-AIDS-002), and the Global Center of Excellence Program (Global Education and Research Center Aiming at the Control of AIDS) from the Japanese Ministry of Education, Science, Sports and Culture. No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: hingatana@acc.ncgm.go.jp

Introduction

Tenofovir disoproxil fumarate (TDF) and abacavir sulfate (ABC) are widely used nucleot(s)ide reverse transcriptase inhibitors (NRTIs) as part of the initial antiretroviral therapy for patients with HIV infection in the developed countries (URL:<http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf>) (URL:http://www.europeanaidscinicalsociety.org/images/stories/EACS-Pdf/1_treatment_of_hiv_infected_adults.pdf). TDF is generally preferred to ABC, since ABC is reported to cause serious hypersensitivity

reaction in 5–8% of the patients and its efficacy in viral suppression is reported to be inferior to TDF among patients with baseline HIV viral load of $>100,000$ copies/ml [1,2]. On the other hand, renal proximal tubular damage and renal dysfunction are well-known adverse effects of TDF [3–9]. A meta-analysis study that compared TDF and other NRTIs concluded that the decline in renal function with TDF use is significant but modest, and the ASSERT study conducted in Europe compared randomly-selected treatment naïve patients who commenced treatment with either TDF or ABC with efavirenz and showed no difference in estimated glomerular filtration

rate (eGFR) between the two groups at 48 weeks [9,10]. To date, the nephrotoxicity of TDF have been regarded as mild and tolerable [2,5–7,9–11].

However, the TDF-related nephrotoxicity has hardly been evaluated in patients with small body weight, who are potentially at higher risk for larger drug exposure and thus, more severe toxicity [12–15]. Indeed, some recent studies including ours reported a higher incidence of TDF-related renal dysfunction among Asian patients with low body weight compared with previous studies on mostly Whites and African Americans with larger body weight [13,16]. Thus, it is important to provide more evidence in support of TDF-associated nephrotoxicity in patients with low body weight since such data can elucidate whether TDF-related nephrotoxicity is as mild in low-body-weighted patients as previously reported in Europe and the USA. This is also important because there is increasing use of TDF in resource-limited settings, where patients are often of relatively small body weight, following the revised 2010 WHO guidelines that recommend TDF as one of the components of first line therapies (URL:http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf) [13,16–19]. To our knowledge, there are no studies that compared renal function in treatment naïve Asian patients who commenced treatment with TDF or ABC.

Based on the above background, the present study was designed to compare the incidence of renal dysfunction and change in eGFR between treatment-naïve Japanese patients with low body weight who started either TDF or ABC as part of the antiretroviral regimen.

Methods

Ethics Statement

This study was approved by the Human Research Ethics Committee of National Center for Global Health and Medicine, Tokyo. All patients included in this study provided a written informed consent for their clinical and laboratory data to be used and published for research purposes. This study has been conducted according to the principles expressed in the Declaration of Helsinki.

Study Subjects

We performed a retrospective, single-center cohort study of HIV-infected Japanese patients using the medical records at the National Center for Global Health and Medicine, Tokyo, Japan. Our facility is one of the largest clinics for patients with HIV infection in Japan with more than 2,700 registered patients. The study population was treatment-naïve patients with HIV infection, aged >17 years, who commenced treatment with either the recommended 300 mg/day dose of TDF or 600 mg/day dose of ABC-containing antiretroviral regimen at our clinic between January 1, 2004 and March 31, 2009. During this inclusion period, all except two patients at our clinic started ART with either ABC or TDF. Patients with an eGFR of >60 ml/min/1.73 m² were enrolled. Patients were followed up until March 31, 2011. They were excluded if they started ART with both TDF and ABC, their follow-up period at our facility was less than 24 weeks after commencement of ART, or if they had started ART at other facilities. Only Japanese patients were included in order to examine a population with comparatively homogenous basic demographics and background. The attending physician selected either TDF or ABC at baseline, and the use of these two drugs was based on the Japanese guidelines, which place both ABC and TDF as the preferred NRTIs (<http://www.haart-support.jp/guideline2011.pdf>, in Japanese). The attending physician also selected

the key drug [non-nucleoside reverse transcriptase inhibitor (NNRTI), protease inhibitor (PI), or integrase inhibitor (INI)]. All patients received standard ART with two NRTIs combined with either PI, NNRTI, or INI.

Measurements

We defined renal dysfunction as more than 25% decrease in eGFR relative to the baseline [13,16,20,21]. The baseline eGFR was estimated for each patient from the average of two successive serum creatinine measurements made closest to and preceding the commencement of antiretroviral therapy by no more than 90 days. Changes in eGFR were plotted from the baseline measurement until the average value of two successive measurements diminished to less than 75% of the baseline, discontinuation of TDF or ABC, or at the end of the follow-up period. Discontinuation of TDF and ABC was the choice of the attending physician, and was based on virologic failure or ART-related side effects other than renal dysfunction. Before the initiation of ART and until suppression of HIV-1 viral load, patients visited our clinic every month. However, after viral load suppression, the visit interval was extended up to every three months. Serum creatinine and eGFR were measured in every visit, and the frequency of measurements was similar in patients on TDF and ABC. eGFR was calculated using the equation from the 4-variable Modification of Diet in Renal Disease (MDRD) study, $eGFR = 186 \times [\text{serum creatinine}]^{-1.154} \times [\text{age}]^{-0.203} \times [0.742 \text{ if patient is female}] \times [1.212 \text{ if patient is African American}]$ [22]. In this study, the primary exposure variable was TDF use over ABC as part of the initial ART.

The potential risk factors for renal dysfunction were determined according to previous studies and collected together with the basic demographics from the medical records [15,23–25]. They included age, sex, body weight, body mass index, (BMI) = {body weight (kg) / [height (m)]²}, baseline laboratory data (CD4 cell count, HIV viral load, and serum creatinine), and presence or absence of other medical conditions (concurrent use of ritonavir-boosted protease inhibitors, concurrent nephrotoxic drugs such as ganciclovir, sulfamethoxazole/trimethoprim, and non-steroidal anti-inflammatory agents, diabetes mellitus defined by using anti-diabetic agents or fasting plasma glucose >126 mg/dl or plasma glucose >200 mg/dl on two different days, co-infection with hepatitis B defined by positive hepatitis B surface antigen, co-infection with hepatitis C defined by positive HCV viral load, hypertension defined by current treatment with antihypertensive agents or two successive measurements of systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg at the clinic, dyslipidemia defined by current treatment with lipid-lowering agents, and current smoking). At our clinic, weight and blood pressure were measured on every visit whereas other variables were measured in the first visit and at least once annually. We used the data on or closest to and preceding the day of starting ART by no more than 90 days.

Statistical analysis

The time to 25% decline in eGFR from the baseline was calculated from the date of commencement of treatment to the date of diagnosis of the above-defined renal dysfunction. Censored cases represented those who discontinued ABC or TDF, dropped out, were referred to other facilities, or at the end of follow-up period. The time from the start of ART to >25% decrease in eGFR was analyzed by the Kaplan Meier method for patients who started TDF (TDF arm) and ABC (ABC arm), and the log-rank test was used to determine the statistical significance. The Cox proportional hazards regression analysis was used to estimate the

impact of TDF use over ABC on the incidence of more than 25% decrease in eGFR relative to the baseline. The impact of each basic demographics, baseline laboratory data, and other medical conditions listed above was also estimated with univariate Cox proportional hazards regression.

To estimate the unbiased prognostic impact of TDF use over ABC for renal dysfunction, we conducted three models using multivariate Cox proportional hazards regression analysis. Model 1 was the aforementioned univariate analysis for TDF use over ABC. Model 2 included age and weight plus model 1 in order to adjust for basic characteristics. In model 3, we added variables with P values <0.05 in univariate analysis for adjustment (these included age per 1 year, weight per 1 kg decrement, CD4 count per 1 μl decrement, HIV viral load per \log_{10}/ml , serum creatinine per 1 mg/dl , concurrent use of nephrotoxic drug(s), hepatitis B infection, and diabetes mellitus). The eGFR and the BMI were excluded from multivariate analysis because of their multicollinearity with age and serum creatinine, and weight, respectively, since eGFR and BMI are gained by the equation of those variables [22,26]. We chose to add weight instead of BMI because our previous work showed that weight was more useful and handy information to estimate the risk for TDF-related nephrotoxicity than BMI [16].

As a sensitivity analysis, creatinine clearance was similarly calculated with Cockcroft-Gault equation for each patient, creatinine clearance = $[(140 - \text{age}) \times \text{weight (kg)}] / (\text{serum creatinine} \times 72) (\times 0.85 \text{ for females})$ [27]. Actual body weight was used for the calculation. The impact of TDF use over ABC for $>25\%$ decrement of creatinine clearance from the baseline was estimated in univariate analysis and multivariate analysis adjusted with the before mentioned variables with Cox proportional hazards model.

To estimate the impact of weight on TDF-related nephrotoxicity, we did subgroup analysis for intertertile baseline body weight categories: ≤ 60 , 61–68, and >68 kg. Then, the abovementioned multivariate analysis with eGFR was conducted for each subgroup.

We also used a repeated measures mixed model to estimate and compare changes in eGFR between ABC and TDF from baseline to 2 years after initiation of ART by 6-month intervals adjusted for baseline eGFR and weight [10]. For each patient, the eGFR values at closest to and preceding 24, 48, 72 and 96 weeks after commencement of ART were collected. In this analysis, censoring occurred at discontinuation of TDF or ABC, leaving care, or reaching the end of the observation period before 96 weeks. Sensitivity analysis with creatinine clearance calculated by Cockcroft-Gault equation was similarly conducted.

Statistical significance was defined at two-sided p values <0.05 . We used hazard ratios (HRs) and 95% confidence intervals (95% CIs) to estimate the impact of each variable on renal dysfunction. All statistical analyses were performed with The Statistical Package for Social Sciences ver. 17.0 (SPSS, Chicago, IL).

Results

The study subjects were 199 patients in the TDF arm and 304 patients in the ABC arm who fulfilled the abovementioned criteria. Table 1 shows the demographics, laboratory data, and medical conditions of the study population at baseline. The majority of the study population was males, comparatively young and had a small stature (median weight, 64 kg, median BMI, 22.2 kg/m^2). More than 80% of the patients in the two arms had ritonavir-boosted PI. In the ABC arm, patients had significantly lower CD4 count ($p=0.006$), were significantly more likely to have hypertension

($p<0.001$), and tended to use more nephrotoxic drugs ($p=0.109$). On the other hand, in the TDF arm, patients had marginally higher baseline eGFR ($p=0.098$) and were significantly more likely to have hepatitis B virus infection ($P<0.001$). However, all other major background parameters were similar in the two groups (Table 1).

More than 25% decrement in eGFR from baseline occurred in 44 patients (22.1%) in the TDF arm and 41 (13.5%) in the ABC arm, with an estimated incidence of 9.84 and 4.55 per 100 person-years, respectively. Figure 1 shows the time from ART initiation to $>25\%$ decrease in eGFR by the Kaplan Meier method in the two groups. Patients who started TDF-containing ART were significantly more likely to develop renal dysfunction, compared to the ABC group ($p=0.001$, Log-rank test). The median time from commencement of ART to occurrence of $>25\%$ decrement in eGFR was 246 days (range, 1–1,339 days) for the TDF arm and 501 days (range, 7–2,022) for ABC arm. The total observation period was 447.2 patient-years [median, 839 days, interquartile range (IQR), 357–1137 days] for the TDF arm and 901.7 patient-years (median, 1,119 days, IQR, 660.5–1509 days) for the ABC arm.

Univariate analysis showed a significant relationship between TDF use and $>25\%$ decrement in eGFR (HR = 1.747; 95%CI, 1.152–2.648; $p=0.009$) (Table 2). Furthermore, old age, small body weight, low baseline CD4 count, high HIV viral load, high eGFR, low serum creatinine, concurrent use of nephrotoxic drugs, hepatitis B infection, and diabetes mellitus were associated with renal dysfunction. On the other hand, concurrent use of ritonavir boosted PIs was not associated with renal dysfunction (HR = 1.220; 95%CI, 0.663–2.244; $p=0.523$). Multivariate analysis identified TDF use as a significant risk for $>25\%$ decrement in eGFR after adjustment for age and weight (adjusted HR = 1.893; 95%CI, 1.243–2.881; $p<0.003$) (Table 3, Model 2), and also after adjustment for other risk factors (adjusted HR = 2.080; 95%CI, 1.339–3.232; $p<0.001$) (Table 3, Model 3). We also conducted a sensitivity analysis using BMI decrement instead of weight as a variable in Table 3, Model 3. The results were almost identical; TDF use over ABC use was a risk for renal dysfunction (adjusted HR 1.957, 95% CI 1.262–3.036, $p=0.003$).

Sensitivity analysis with creatinine clearance confirmed the abovementioned findings: both univariate and multivariate analyses showed that TDF use was significantly associated with $>25\%$ decrement in eGFR (univariate analysis: HR = 2.212; 95%CI, 1.340–3.653; $p=0.002$) (multivariate analysis: adjusted HR = 2.544; 95%CI, 1.493–4.335; $p=0.001$).

Subgroup analysis of the patients stratified by intertertile baseline body weight showed that the lower the baseline body weight, the more evident the impact of TDF on renal dysfunction (≤ 60 kg: adjusted HR = 2.771; 95%CI, 1.494–5.139; $p=0.001$) (61–68 kg: adjusted HR = 1.908; 95%CI, 0.764–4.768; $p=0.167$) (>68 kg: adjusted HR = 0.997; 95%CI, 0.318–3.121; $p=0.995$) (Table 4). These findings suggest that there is the effect modification by baseline body weight on TDF-associated renal dysfunction.

Data analysis by repeated measures mixed models showed a significant decrease in adjusted mean eGFR from the baseline to 96 weeks in both groups (TDF: $-9.984 \text{ ml}/\text{min}/1.73\text{m}^2$, 95%CI -12.05 to $-7.914 \text{ ml}/\text{min}/1.73\text{m}^2$, $p<0.001$; ABC: $-5.393 \text{ ml}/\text{min}/1.73\text{m}^2$, 95%CI -7.087 to $-3.699 \text{ ml}/\text{min}/1.73\text{m}^2$, $p<0.001$) (Figure 2). There was a statistically significant interaction between the two arms over time ($p=0.003$), indicating that adjusted mean eGFR decreased more significantly in the TDF group than in the ABC group after initiation of ART. Analysis of eGFR in each group demonstrated a rapid decrease during the first 24 weeks,

Table 1. Baseline demographics and laboratory data of patients who received tenofovir- and abacavir-based antiretroviral therapy (n = 503).

	TDF (n = 199)	ABC (n = 304)	P value
Sex (male), n (%)	196 (98.5)	296 (97.4)	0.539
Median (IQR) age	36 (31–44)	37 (31–43)	0.436
Median (IQR) weight (kg)	64 (58–69)	64 (58.0–70.9)	0.426
Median (IQR) BMI (kg/m ²)	22.1 (20.4–23.9)	22.2 (20.3–24.6)	0.321
Median (IQR) eGFR (ml/min/1.73m ²)	119.4 (103.0–135.0)	115.6 (102.4–132.2)	0.098
Median (IQR) serum creatinine (mg/dl)	0.74 (0.67–0.84)	0.75 (0.68–0.83)	0.250
Median (IQR) CD4 count (/μl)	199 (109–272)	178.5 (75.3–234.8)	0.006
Median (IQR) HIV RNA viral load (log ₁₀ /ml)	4.63 (4.20–5.20)	4.74 (4.23–5.20)	0.731
Ritonavir-boosted protease inhibitors, n (%)	173 (86.9)	256 (84.2)	0.441
Protease inhibitors (unboosted), n (%)	5 (2.5)	20 (6.6)	0.038
NNRTIs, n (%)	16 (8.0)	26 (8.6)	0.848
INIs, n (%)	5 (2.5)	2 (0.7)	0.119
Hypertension, n (%)	5 (2.5)	53 (17.4)	<0.001
Dyslipidemia, n (%)	4 (2.0)	4 (1.3)	0.718
Diabetes mellitus, n (%)	8 (4.0)	12 (3.9)	1.000
Concurrent use of nephrotoxic drugs, n (%)	65 (32.7)	121 (39.8)	0.109
Hepatitis B, n (%)	35 (17.6)	9 (3.0)	<0.001
Hepatitis C, n (%)	7 (3.5)	7 (2.3)	0.421
Current smoker, n (%)	93 (46.7)	149 (49.3)	0.585

TDF: tenofovir, ABC: abacavir, IQR: interquartile range, BMI: body mass index, eGFR: estimated glomerular filtration rate, NNRTI: non- nucleoside reverse transcriptase inhibitor, INI: integrase inhibitor.
doi:10.1371/journal.pone.0029977.t001




Figure 1. Kaplan-Meier curve showing the time to renal dysfunction in patients treated with TDF or ABC. Compared to treatment-naïve patients who commenced treatment with ABC, those on TDF were more likely to develop >25% fall in eGFR (p = 0.001, Log-rank test). TDF: tenofovir, ABC: abacavir, ART: antiretroviral therapy, eGFR: estimated glomerular filtration rate.
doi:10.1371/journal.pone.0029977.g001

Table 2. Univariate analysis to estimate the risk of various factors in inducing more than 25% fall in eGFR.

	Hazard ratio	95% CI	P value
TDF vs. ABC use	1.747	1.152–2.648	0.009
Female gender	0.048	0.000–16.93	0.310
Age per 1 year	1.031	1.011–1.051	0.002
Weight per 1 kg decrement	1.047	1.023–1.072	<0.001
BMI per 1 kg/m ² decrement	1.152	1.066–1.244	<0.001
CD4 count per 1 / μ l decrement	1.006	1.004–1.008	<0.001
HIV viral load per log ₁₀ /ml	1.562	1.179–2.071	0.002
Ritonavir-boosted protease inhibitors	1.220	0.663–2.244	0.523
Baseline eGFR per 1 ml/min/1.73m ²	1.009	1.005–1.014	<0.001
Baseline serum creatinine per 1mg/dl	0.016	0.003–0.086	<0.001
Concurrent nephrotoxic drug	2.134	1.417–3.214	<0.001
Hepatitis B	1.866	1.038–3.356	0.037
Hepatitis C	1.721	0.631–4.695	0.289
Diabetes mellitus	2.558	1.181–5.540	0.017
Hypertension	0.865	0.448–1.669	0.664
Current smoking	0.989	0.657–1.489	0.958

eGFR: estimated glomerular filtration rate, CI: confidence interval, TDF: tenofovir, ABC: abacavir, BMI: body mass index.
doi:10.1371/journal.pone.0029977.t002

followed by a plateau until 96 weeks. In sensitivity analysis with creatinine clearance calculated by Cockcroft-Gault equation, the result was the same; a significant decrease from the baseline to 96 weeks in both groups (TDF: -10.62 ml/min, 95%CI -13.78 to -7.458 ml/min; ABC: -4.325 ml/min, 95%CI -6.893 to -1.756 ml/min) and significantly more eGFR decrement in the TDF group ($p = 0.019$).

Discussion

In this observational Japanese cohort, treatment-naïve patients who started TDF-containing ART experienced eGFR decline of >25% approximately twice as likely compared to those treated with ABC-containing regimen. Univariate and multivariate analyses identified TDF use as an independent risk factor for

Table 4. Multivariate analysis to estimate the risk of TDF-over ABC-based antiretroviral therapy in the induction of more than 25% fall in eGFR according to baseline body weight.

	Adjusted HR	95% CI	P value
Baseline body weight \leq 60 kg (n = 171)			
TDF vs. ABC use	2.771	1.494–5.139	0.001
Baseline body weight 61–68 kg (n = 167)			
TDF vs. ABC use	1.908	0.764–4.768	0.168
Baseline body weight >68 kg (n = 165)			
TDF vs. ABC use	0.997	0.318–3.121	0.995

TDF use was adjusted with the same variables indicated in Model 3, Table 3: age per 1 year, weight per 1 kg decrement, CD4 count per 1 / μ l decrement, HIV viral load per log₁₀/ml, serum creatinine per 1 mg/dl, concurrent use of nephrotoxic drugs, hepatitis B infection, and diabetes mellitus.

doi:10.1371/journal.pone.0029977.t004

renal dysfunction. Subgroup analysis showed that the effect of TDF on renal dysfunction was more evident in patients with lower body weight. Furthermore, eGFR decrement was significantly larger in the TDF group than in ABC group over the 2-year observation period.

In our previous study, we demonstrated a high incidence of TDF-associated nephrotoxicity in patients with low body weight, and the use of a robust statistical model indicated a greater decline in renal function in patients of low body weight treated with TDF [16]. The results of the present study further emphasize the importance of low body weight as a risk factor for TDF-related nephrotoxicity by showing that in a cohort of patients with low body weight, the incidence of renal dysfunction was twice higher with TDF use than with ABC use.

Among the studies designed to compare renal function after the commencement of TDF and ABC-containing ART for treatment-naïve patients, our cohort had the lowest median body weight (64 kg). This is lower than the median body weight of patients of the ASSERT study conducted in European countries (72 kg) [10]. The

Table 3. Multivariate analysis to estimate the risk of TDF- over ABC-based antiretroviral therapy in inducing more than 25% fall in eGFR.

	Model 1 Crude		Model 2 Adjusted		Model 3 Adjusted	
	HR	95% CI	HR	95%CI	HR	95%CI
TDF vs. ABC use [†]	1.747	1.152–2.648	1.893	1.243–2.881	2.080	1.339–3.232
Age per 1 year			1.029	1.010–1.048	1.020	1.000–1.040
Weight per 1 kg decrement [†]			1.046	1.022–1.071	1.028	1.005–1.052
CD4 count per 1 / μ l decrement [†]					1.004	1.002–1.007
HIV viral load per log ₁₀ /ml					1.048	0.749–1.466
Serum creatinine per 1 mg/dl [†]					0.053	0.009–0.304
Use of nephrotoxic drug					1.309	0.825–2.077
Hepatitis B					1.070	0.573–2.000
Diabetes mellitus					1.565	0.684–3.582

[†] $P < 0.05$ in Model 3.

TDF: tenofovir, ABC: abacavir, eGFR: estimated glomerular filtration rate, HR: hazard ratio, CI: confidence interval.
doi:10.1371/journal.pone.0029977.t003




Figure 2. Changes in eGFR in patients treated with TDF or ABC between baseline and 96 weeks. The fall in eGFR was significantly greater in the TDF group than the ABC group ($p = 0.003$). Data are adjusted mean \pm 95% confidence interval. eGFR: estimated glomerular filtration rate, TDF: tenofovir, ABC: abacavir.

doi:10.1371/journal.pone.0029977.g002

results of the present study on TDF-related nephrotoxicity differ from the findings of randomized clinical trials that demonstrated no major change in renal function of TDF- and ABC-treated patients over 48–96 week follow-up [2,10,11]. The discrepant results might arise from differences between observational cohort and clinical trials, since observational studies tend to express the results in “real world setting” whereas clinical trials include patients who fulfill more strict criteria, therefore with better profile [9]. The discrepant results could be also due to the use of different definitions for renal dysfunction in these studies. However, the discrepant results could also reflect the difference in median body weight between the present study and these clinical trials. The results of our subgroup analysis support this hypothesis by showing that the effect of TDF on renal dysfunction was more evident in patients with low body weight. Apart from being low-body-weighted, the patients in this study did not appear to have many of other established risks for TDF-related nephrotoxicity; they were comparatively young, had relatively stable CD4 count, and had only a few co-morbidities (Table 1). Although the majority concurrently used ritonavir-boosted PIs, which are a probable risk for TDF-related nephrotoxicity, ritonavir-boosted PIs were not significantly associated with renal dysfunction in our cohort (Table 2) [24].

Changes in eGFR in those patients treated with TDF-containing ART were characterized by a rapid decline during the first 24 weeks of therapy, followed by a plateau until 96 weeks (Fig. 2). This finding is consistent with that reported from the Johns Hopkins group [9,28]. Together with the finding that the median time from commencement of ART to the >25% decline in eGFR in the TDF-treated patients was 246 days, these results suggest that careful monitoring of renal function is particularly warranted in the first year of TDF-based therapy. Thus, we suggest that renal function should be monitored by measurement of serum creatinine at least once annually in resource-limited settings and twice annually in resource-rich settings in patients starting TDF-containing ART, especially those with baseline body weight <60 kg.

The Department of Health and Human Services guideline for the treatment of HIV infection in the U.S. lists ABC as an

alternative NRTI because it can potentially cause serious hypersensitivity reaction and cardiovascular diseases (URL:<http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf>). However, some international guidelines consider both TDF and ABC as the preferred NRTIs under the condition that ABC should be used with caution in patients with viral load >100,000 copies/mL, based on the low incidence of ABC-related hypersensitivity among HLA-B*5701-negative population and the controversial association between ABC and cardiovascular diseases [1,29–32] (URL: http://www.europeanaidscinicalsociety.org/images/stories/EACS-Pdf/1_treatment_of_hiv_infected_adults.pdf) (<http://www.haart-support.jp/guideline2011.pdf> in Japanese). The present study, together with our previous analysis that demonstrated preferential TDF-related nephrotoxicity in patients with low body weight, emphasize the advantage of ABC over TDF with regard to prognosis of renal function in low body weight patients [16].

TDF is the prodrug of acyclic nucleotide analog tenofovir, which is excreted by both glomerular filtration and active tubular secretion. Tenofovir is considered to cause mitochondrial damage in proximal renal tubular cells [33]. The concentration of tenofovir in the proximal renal tubules could be augmented with the complex interactions of pharmacological, environmental, and genetic factors, including small body weight, consequently resulting in renal tubular dysfunction [34]. Body weight has been identified as an important factor in TDF-related nephrotoxicity not only in clinical trials, but also in *in vitro* and pharmacokinetic studies [35–37].

The present study has several limitations. First, because of its retrospective nature, it was not possible to control the baseline characteristics of the enrolled patients. Thus, it is possible that patients with potential risk for TDF-related nephrotoxicity were not prescribed TDF. A proportion of patients treated with ABC had low CD4 count and others were hypertensive, both conditions are known risk factors for renal dysfunction [23,25]. However, for these reasons, the incidence of TDF-associated renal dysfunction might have been underestimated. Second, the definition of TDF-related nephrotoxicity, especially the criteria used to evaluate proximal renal tubular damage, is not uniformly established in the field and is different in the published studies. Accordingly, we

decided to adopt changes in eGFR, instead of parameters for proximal renal tubular damage. Using the eGFR as a marker for TDF-associated renal dysfunction, our results might have underestimated the incidence of TDF-related renal tubular dysfunction. However, the result of this study could be informative to resource-limited settings, where it is difficult to evaluate renal tubular markers. The rationale and limitation of adopting more than 25% decrement in eGFR as the criterion for renal dysfunction were discussed in detail in our previous study [16]. Third, our cohort was characterized by the high prevalence of ritonavir-boosted PI use, which is considered by some groups a risk for TDF-related nephrotoxicity [24]. While it is difficult to completely exclude the impact of concurrent ritonavir-boosted PI in this study, it should be noted that the use of ritonavir-boosted PIs did not correlate with renal dysfunction in univariate analysis in this cohort (Table 2). Fourth, the study subjects were mainly men (mostly men who have sex with men and very few injection drug users). Further studies are needed to determine whether the findings of this study are also applicable to females, patients with different route of transmissions, and patients of different racial background.

In conclusion, the present study demonstrated a high incidence of renal dysfunction with TDF use, compared to ABC, among treatment-naïve patients with low body weight. TDF use was identified as an independent risk for renal dysfunction in a

statistical model that included TDF as a primary exposure. At 96 weeks, patients with TDF showed greater eGFR decrement than patients treated with ABC. TDF is certainly a drug of choice in the treatment of HIV infection, but the importance of close monitoring of renal function in patients with small body weight, especially those with baseline body weight <60 kg should be emphasized for early detection of TDF-related nephrotoxicity. Further studies are warranted to elucidate the long-term prognosis of renal function with TDF use in patients with low body weight.

Acknowledgments

The authors thank Fumihiko Hinoshita, Ai Hori, Daisuke Tasato, Mahoko Kamimura, Kunio Yanagisawa, Daisuke Mizushima, Yohei Hamada, Aki Hashimoto, Akio Chiba, Yuko Yamauchi, Taiichiro Kobayashi, Kumi Tamura, and all other clinical staff at the AIDS Clinical Center for their help in completion of this study.

Author Contributions

Conceived and designed the experiments: TN HK HG TS EK JT SO. Performed the experiments: TN HK TS TA KW EK MH. Analyzed the data: TN HK HG TS HH HY K. Tsukada MH K. Teruya YK. Contributed reagents/materials/analysis tools: TA KW HH JT HY K. Tsukada MH K. Teruya YK. Wrote the paper: TN HK HG TS EK SO.

References

- Mallal S, Phillips E, Carosi G, Molina JM, Workman C, et al. (2008) HLA-B*5701 screening for hypersensitivity to abacavir. *N Engl J Med* 358: 568–579.
- Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, et al. (2009) Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. *N Engl J Med* 361: 2230–2240.
- Peyriere H, Reynes J, Rouanet I, Daniel N, de Boever CM, et al. (2004) Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. *J Acquir Immune Defic Syndr* 35: 269–273.
- Verhelst D, Monge M, Meynard JL, Fouqueray B, Mougenot B, et al. (2002) Fanconi syndrome and renal failure induced by tenofovir: a first case report. *Am J Kidney Dis* 40: 1331–1333.
- Winston A, Amin J, Mallon P, Marriott D, Carr A, et al. (2006) Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. *HIV Med* 7: 105–111.
- Fux CA, Simcock M, Wolbers M, Bucher HC, Hirschel B, et al. (2007) Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. *Antivir Ther* 12: 1165–1173.
- Gallant JE, Winston JA, DeJesus E, Pozniak AL, Chen SS, et al. (2008) The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naïve patients. *AIDS* 22: 2155–2163.
- Kinai E, Hanabusa H (2009) Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. *AIDS Res Hum Retroviruses* 25: 387–394.
- Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, et al. (2010) Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. *Clin Infect Dis* 51: 496–505.
- Post FA, Moyle CJ, Stellbrink HJ, Domingo P, Podzamczak D, et al. (2010) Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naïve, HIV-1-infected adults: 48-week results from the ASSERT study. *J Acquir Immune Defic Syndr* 55: 49–57.
- Smith KY, Patel P, Fine D, Bellos N, Sloan L, et al. (2009) Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. *AIDS* 23: 1547–1556.
- Gayet-Ageron A, Ananworanich J, Jupimai T, Chetchotisakd P, Prasithsirikul W, et al. (2007) No change in calculated creatinine clearance after tenofovir initiation among Thai patients. *J Antimicrob Chemother* 59: 1034–1037.
- Chaisiri K, Bowonwatanuwong C, Kasattrat N, Kiertiburanakul S (2010) Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight. *Curr HIV Res* 8: 504–509.
- Reid A, Stohr W, Walker AS, Williams IG, Kityo C, et al. (2008) Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. *Clin Infect Dis* 46: 1271–1281.
- Gatanaga H, Tachikawa N, Kikuchi Y, Teruya K, Genka I, et al. (2006) Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. *AIDS Res Hum Retroviruses* 22: 744–748.
- Nishijima T, Komatsu H, Gatanaga H, Aoki T, Watanabe K, et al. (2011) Impact of Small Body Weight on Tenofovir-Associated Renal Dysfunction in HIV-Infected Patients: A Retrospective Cohort Study of Japanese Patients. *PLoS One* 6: e22661.
- Bygrave H, Kranzer K, Hilderbrand K, Jouquet G, Goemaere E, et al. (2011) Renal safety of a tenofovir-containing first line regimen: experience from an antiretroviral cohort in rural Lesotho. *PLoS One* 6: e17609.
- De Beudrap P, Diallo MB, Landman R, Gueye NF, Ndiaye I, et al. (2010) Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215). *AIDS Res Hum Retroviruses* 26: 1221–1227.
- Brennan A, Evans D, Maskew M, Naicker S, Ive P, et al. (2011) Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. *AIDS* 25: 1603–1609.
- Bash LD, Coresh J, Kottgen A, Parekh RS, Fulop T, et al. (2009) Defining incident chronic kidney disease in the research setting: The ARIC Study. *Am J Epidemiol* 170: 414–424.
- Chuc CD, Edwards NC, Davis LJ, Steeds RP, Townend JN, et al. (2011) Serum phosphate but not pulse wave velocity predicts decline in renal function in patients with early chronic kidney disease. *Nephrol Dial Transplant*.
- Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, et al. (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. *Ann Intern Med* 145: 247–254.
- Gupta SK, Eustace JA, Winston JA, Boydston II, Ahuja TS, et al. (2005) Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. *Clin Infect Dis* 40: 1559–1585.
- Goicoechea M, Liu S, Best B, Sun S, Jain S, et al. (2008) Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. *J Infect Dis* 197: 102–108.
- Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, et al. (2007) The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. *AIDS* 21: 1273–1281.
- Garrow JS, Webster J (1985) Quetelet's index (W/H²) as a measure of fatness. *Int J Obes* 9: 147–153.
- Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. *Nephron* 16: 31–41.
- Gallant JE, Moore RD (2009) Renal function with use of a tenofovir-containing initial antiretroviral regimen. *AIDS* 23: 1971–1975.
- Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P (2011) Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. *Clin Infect Dis* 53: 84–91.
- Nolan D, Gaudieri S, Mallal S (2003) Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity? *J HIV Ther* 8: 36–41.
- Sun HY, Hung CC, Lin PH, Chang SF, Yang CY, et al. (2007) Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. *J Antimicrob Chemother* 60: 599–604.
- Gatanaga H, Honda H, Oka S (2008) Pharmacogenetic information derived from analysis of HLA alleles. *Pharmacogenomics* 9: 207–214.

33. Kohler JJ, Hosseini SH, Hoying-Brandt A, Green E, Johnson DM, et al. (2009) Tenofovir renal toxicity targets mitochondria of renal proximal tubules. *Lab Invest* 89: 513–519.
34. Post FA, Holt SG (2009) Recent developments in HIV and the kidney. *Curr Opin Infect Dis* 22: 43–48.
35. Jullien V, Treluyer JM, Rey E, Jaffray P, Krivine A, et al. (2005) Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy. *Antimicrob Agents Chemother* 49: 3361–3366.
36. Van Rompay KK, Durand-Gasselín L, Brignolo LL, Ray AS, Abel K, et al. (2008) Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. *Antimicrob Agents Chemother* 52: 3144–3160.
37. Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, et al. (2008) Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. *Antimicrob Agents Chemother* 52: 631–637.

Selection and Accumulation of an HIV-1 Escape Mutant by Three Types of HIV-1-Specific Cytotoxic T Lymphocytes Recognizing Wild-Type and/or Escape Mutant Epitopes

Tomohiro Akahoshi,^a Takayuki Chikata,^a Yoshiko Tamura,^a Hiroyuki Gatanaga,^{a,b} Shinichi Oka,^{a,b} and Masafumi Takiguchi^a

Center for AIDS Research, Kumamoto University, Kumamoto, Japan,^a and AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan^b

It is known that cytotoxic T lymphocytes (CTLs) recognizing HIV-1 escape mutants are elicited in HIV-1-infected individuals, but their role in the control of HIV-1 replication remains unclear. We investigated the antiviral ability of CTLs recognizing the HLA-A*24:02-restricted Gag28-36 (KYKLVKLVW) epitope and/or its escape mutant (KYRLKLVW) elicited in the early and chronic phases of the infection. Wild-type (WT)-epitope-specific CTLs, as well as cross-reactive CTLs recognizing both WT and K30R (3R) epitopes, which were predominantly elicited at early and/or chronic phases in HLA-A*24:02⁺ individuals infected with the WT virus, suppressed the replication of the WT virus but failed to suppress that of the 3R virus, indicating that the 3R virus was selected by these 2 types of CTLs. On the other hand, cross-reactive and 3R-specific CTLs, which were elicited in those infected with the 3R virus, did not suppress the replication of either WT or 3R virus, indicating that these CTLs did not contribute to the control of 3R virus replication. High accumulation of the 3R mutation was found in a Japanese population recently recruited. The selection and accumulation of this 3R mutation resulted from the antiviral ability of these Gag28-specific CTLs and high prevalence of HLA-A*24:02 in a Japanese population. The present study highlighted the mechanisms for the roles of cross-reactive and mutant-epitope-specific CTLs, as well as high accumulation of escape mutants, in an HIV-1-infected population.

Human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocytes (CTLs) play an important role in the control of HIV-1 during the acute and chronic phases of an HIV-1 infection (22, 40). However, HIV-1-specific CTLs cannot completely eliminate HIV-1-infected cells, because HIV-1 escapes from CTL-mediated immune pressure by various mechanisms, such as selection of escape mutations, Nef-mediated HLA class I downregulation, and skewed maturation of memory HIV-specific CD8⁺ T lymphocytes (5, 8, 9). The most documented escape mechanism is acquisition of amino acid mutations within the CTL epitope and/or its flanking regions. These mutations lead to reduced ability of peptide to bind to HLA class I molecules, impaired T cell receptor (TCR) recognition, and defective epitope generation (21, 31). These escape mechanisms are involved in impaired activities of HIV-1-specific CTLs to kill target cells infected with escape mutant virus and to suppress HIV-1 replication, contributing to the selection of escape mutant viruses (5, 10, 13, 20, 29, 35, 41).

There is growing evidence that escape mutations selected by HLA class I-restricted CTLs accumulate at the population level (7, 28, 36). The accumulation of escape mutants may affect the clinical outcomes for HIV-1-infected individuals (11, 37, 38). On the other hand, it is known that CTLs recognizing escape mutants are elicited after the emergence of the escape mutant selected by wild-type (WT) epitope-specific CTLs (2, 4, 12, 15, 33, 39). The escape mutant-specific CTLs were also elicited in new hosts carrying the same restricted HLA allele when they were infected with the mutant (15). Several studies showed that CTLs cross-recognizing the WT and its escape mutant epitopes are elicited before or after the emergence of the escape mutant in the same hosts (18, 25, 26, 33, 34). However, the antiviral abilities of these cross-reactive CTLs remain unknown, since the recognition of cross-reactive CTLs for synthesized epitope peptides

was characterized by using the enzyme-linked immunosorbent spot assay (ELISPOT) or ⁵¹Cr cytotoxic assay in those studies. We previously showed that HLA-A*24:02-restricted Nef 138-specific CTLs recognizing an escape mutant had weaker ability to suppress the replication of the mutant virus than that of the WT virus (15). However, it still remains unclear whether cross-reactive or escape mutant-specific CTLs contribute to the control of HIV-1, since the CTLs have not been analyzed in detail.

To clarify the abilities of cross-reactive and escape mutant-specific CTLs to recognize HIV-1-infected cells, we analyzed CTLs specific for HLA-A*24:02-restricted HIV-1 Gag28-36 (KYKLVKLVW; Gag28), which is the only immunodominant Gag epitope presented by this HLA class I allele (24). Since HLA-A*24:02 is found in approximately 70% of the Japanese population (42), the mutants of HLA-A*24:02-restricted epitopes may accumulate in HIV-1-infected Japanese individuals. We previously suggested that K30R (3R) in the Gag28 epitope is an escape mutation from HLA-A*24:02-restricted Gag28-specific CTLs (30) and that CTLs recognizing 3R are elicited in HIV-1-infected HLA-A*24:02⁺ individuals (46). From these studies, we hypothesized that cross-reactive CTLs recognizing WT and 3R mutant epitopes and/or 3R-specific CTLs are elicited in HLA-A*24:02⁺ HIV-1-infected individuals after the 3R mutant is selected and in new 3R virus-infected hosts carrying HLA-A*24:02. Here, we investigated the elicitation of Gag28-specific CTLs in 12 HLA-A*24:02⁺ HIV-1-

Received 3 October 2011 Accepted 23 November 2011

Published ahead of print 7 December 2011

Address correspondence to Masafumi Takiguchi, masafumi@kumamoto-u.ac.jp.

Copyright © 2012, American Society for Microbiology. All Rights Reserved.

doi:10.1128/JVI.06470-11

infected Japanese individuals who could be monitored from the early phase to the chronic phase of an HIV-1 infection, as well as the abilities of cross-reactive, 3R mutant-specific, and WT-specific CTLs to kill WT or 3R virus-infected cells and to suppress the replication of the WT or 3R virus. In addition, we investigated the accumulation of the 3R mutation in HIV-1-infected nonhemophiliac Japanese individuals, as well as in Japanese hemophiliacs who had been infected around 1983. The results clarified the role of CTLs recognizing the WT and/or 3R epitope in high accumulation of the 3R mutant in HIV-1-infected Japanese individuals.

MATERIALS AND METHODS

Samples from HIV-1-infected individuals. This study was approved by the ethics committee of Kumamoto University and the National Center for Global Health and Medicine. Informed consent was obtained from all individuals according to the Declaration of Helsinki. For sequence analysis, blood specimens were collected in EDTA. Plasma and peripheral blood mononuclear cells (PBMCs) were separated from whole blood. HLA types were determined by standard sequence-based genotyping. Twelve HLA-A*24:02⁺ individuals who could be monitored from the early to the chronic phase of an HIV-1 infection were recruited for CTL analysis. Early HIV-1 infection was confirmed by seroconversion within 6 months or by an increasing number and density of bands on Western blots. Four-hundred fifty-one chronically HIV-1-infected individuals were also recruited for sequence analysis.

Cells. C1R cells expressing HLA-A*24:02 (C1R-A2402) and 721.221 cells expressing CD4 and HLA-A*24:02 (721.221-CD4-A2402) were previously generated (27, 30). These cells were cultured in RPMI 1640 medium containing 5 to 10% fetal bovine serum (FBS) and 0.15 mg/ml hygromycin B. MAGIC-5 cells (CCR5-transfected HeLa-CD4/long terminal repeat- β -galactosidase [LTR- β -Gal] cells) were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% FBS as described previously (17).

Induction of Gag28-specific T cells. PBMCs from HIV-1-infected HLA-A*24:02⁺ individuals were stimulated with WT or 3R peptide (1 μ M) in culture medium (RPMI 1640 containing 10% FBS and 200 U/ml human recombinant interleukin-2 [rIL-2]). After 14 days, the cultured PBMCs were tested for gamma interferon (IFN- γ) production by performing an intracellular cytokine staining (ICC) assay.

ICC assay. C1R-A2402 cells were prepulsed or not with the WT or 3R peptide at concentrations from 0.1 to 1,000 nM at 37°C for 1 h and then were washed twice with RPMI 1640 containing 10% FBS. PBMCs cultured for 2 weeks after peptide stimulation were incubated with the C1R-A2402 cells in a 96-U plate (Nunc) at 37°C. Brefeldin A (10 μ g/ml) was added after a 2-h incubation, and then the cells were incubated for an additional 4 h. Subsequently, the cells were stained with Pacific-blue-conjugated anti-CD8 monoclonal antibody (MAb) (BD Biosciences) and 7-aminocoumarin D (7-AAD) (BD Biosciences) at 4°C for 30 min, after which the cells were fixed with 4% paraformaldehyde solution and rendered permeable with permeabilization buffer (0.1% saponin and 10% FBS in phosphate-buffered saline) at 4°C for 10 min. Thereafter the cells were stained with fluorescein isothiocyanate (FITC)-conjugated anti-IFN- γ MAb (BD Biosciences) at 4°C for 30 min and then washed twice with the permeabilization buffer. The percentage of CD8⁺ cells producing IFN- γ was analyzed by flow cytometry (FACSCanto II).

Generation of Gag28-specific CTL clones. Gag28-specific CTL clones were generated from Gag28-specific bulk-cultured T cells by limiting dilution in 96-U plates, together with 200 μ l of cloning mixture (1 \times 10⁶ irradiated allogeneic PBMCs from healthy donors and 1 \times 10⁵ irradiated C1R-A2402 cells prepulsed with the WT or 3R peptide at a concentration of 1 μ M in RPMI 1640 containing 10% FBS, 200 U/ml rIL-2, and 2.5% phytohemagglutinin [PHA] soup). After 14 to 21 days in culture, the growing cells were tested for cytotoxic activity by performing the standard

chromium release assay. Since TCRs on these CTL clones were not sequenced, it is still possible that they were oligonucleotide clones.

HIV-1 clones. An infectious provirus, HIV-1 pNL-432, was reported previously (1). NL-432gagSF2 and NL-432gagSF2-3R were previously generated (30).

Assay of cytotoxicity of CTL clones toward target cells prepulsed with the epitope peptide. The cytotoxic activities of Gag28-specific CTL clones were determined by use of the standard chromium release assay, as described previously (15). Briefly, 721.221-CD4-A2402 cells were incubated with 100 μ Ci of Na₂⁵¹CrO₄ in saline for 1 h and then washed 3 times with RPMI 1640 containing 10% newborn calf serum. The labeled target cells (2 \times 10³/well) were prepulsed with the WT or 3R peptide at concentrations of 1 to 1,000 nM for 1 h and then cocultured at 37°C for 4 h with effector cells at an effector-to-target (E:T) ratio of 1:1 in 96-U plates (Nunc). The supernatants were collected and analyzed with a gamma counter. Spontaneous ⁵¹Cr release was determined by measuring the counts per minute in supernatants from wells containing only target cells (cpm spn). Maximum ⁵¹Cr release was determined by measuring the cpm in supernatants from wells containing target cells in the presence of 2.5% Triton X-100 (cpm max). Specific lysis was defined as (cpm exp - cpm spn)/(cpm max - cpm spn) \times 100, where "cpm exp" is the counts per minute in the supernatant in the wells containing both target and effector cells.

Assay of cytotoxicity of CTL clones toward target cells infected with HIV-1. 721.221-CD4-A2402 cells were infected with WT or 3R virus, and then the infection rates were determined by detecting intracellular p24 antigen (Ag)-positive cells stained with FITC-conjugated anti-p24 Ag MAb (KC57-FITC; BD Biosciences). When approximately 50% of the total cells were p24 Ag-positive cells, they were used as target cells. The ⁵¹Cr-labeled target cells (2 \times 10³/well) were cocultured with effector cells at E:T ratios of 0:1 to 2:1 in 96-U plates at 37°C for 6 h. The supernatants were collected and analyzed with a gamma counter.

Generation of HLA-peptide tetrameric complexes. HLA class I-peptide tetrameric complexes (tetramers) were synthesized as previously described (3). The WT or 3R peptide was added to the refolding solution containing the biotinylation sequence-tagged extracellular domain of the HLA-A*24:02 molecule and β 2 microglobulin. The purified monomer complexes were mixed with phycoerythrin (PE)-labeled streptavidin (Molecular Probes) at a molar ratio of 4:1.

Tetramer binding assay. CTL clones were stained with PE-conjugated tetramer at concentrations of 1 to 100 nM at 37°C for 30 min. After 2 washes with RPMI 1640 containing 10% FBS (R10), the cells were stained with FITC-conjugated anti-CD8 MAb and 7-AAD at 4°C for 30 min. Thereafter, the cells were washed twice with R10 and then analyzed by flow cytometry (FACSCanto II). The mean fluorescence intensity (MFI) of tetramer-positive cells among CD8-positive cells was calculated.

Replication suppression assay. The ability of Gag28-specific CTLs to suppress HIV-1 replication was examined as previously described (43). CD4⁺ T cells were isolated from PBMCs of healthy HLA-A*24:02⁺ donors and incubated with a given HIV-1 clone at 37°C for 6 h. After 3 washes with R10, the cells (3 \times 10⁴/well) were cocultured with Gag28-specific CTL clones at E:T ratios of 0.1:1 to 1:1 in R10 containing 1% nonessential amino acid solution and 1% 100 mM sodium pyruvate (complete medium) plus 200 U/ml rIL-2. From day 3 to day 7 postinfection, a 30- μ l volume of culture supernatant was collected, and the volume removed was replaced with fresh medium. The concentration of p24 Ag was measured by using an enzyme-linked immunosorbent assay (ELISA) (HIV-1-p24-Ag ELISA kit; ZeptoMetrix).

Replication kinetics assay. The replication kinetics of the WT and 3R viruses were examined as previously described (17). After CD4⁺ T cells (2 \times 10⁶) had been exposed to each infectious virus preparation (500 blue cell-forming units in MAGIC-5 cells) for 2 h and washed twice with R10, they were cultured in 1 ml of R10 containing 1% nonessential amino acid solution and 1% 100 mM sodium pyruvate (complete medium) plus 200 U/ml rIL-2. Then, 0.1 ml of the culture supernatant was collected from

day 2 to day 10 postinfection, and the volume removed was replaced with fresh medium. The concentration of p24 Ag in the supernatant was measured by using ELISA. Replication kinetics assays were performed in triplicate.

Sequence of autologous virus. Viral RNA was extracted from plasma samples from HIV-1-infected individuals by using a QIAamp MinElute virus spin kit (Qiagen). For clone sequencing, cDNA was synthesized from the RNA with SuperScript III and Random Primers (Invitrogen), and the Gag region was amplified by nested PCR with *Taq* DNA polymerase (Promega). Then, the PCR products were gel purified and cloned with a TOPO TA cloning kit (Invitrogen). For bulk sequencing, the Gag region was amplified from the RNA by using the SuperScript III One-Step RT-PCR System with Platinum *Taq* DNA Polymerase (Invitrogen) and Gag-specific primers, and then the second PCR was done. We prepared the Gag-specific primer sets shown below. For clone sequencing, 5'-TTTTT GACTAGCGGAGGCTAGAA-3' and 5'-CACAAATAGAGGGTTGCTAC TGT-3' were used for the first PCR and 5'-GGGTGCGAGAGCGTCCG TATTAAGC-3' and 5'-TAAGTCTTCTGATCCTGTCTG-3' for the second PCR. For bulk sequence, 5'-TCTCTCGACGCAGGACTC-3' and 5'-AGGGTTCCTTTGGTCCTTGT-3' were employed for the reverse transcription (RT)-PCR and 5'-TCTCTCGACGCAGGACTC-3' and 5'-TCTCTACTGGGATAGGTG-3' for the second PCR. All DNA sequencing was performed by using a BigDye Terminator cycle-sequencing kit (Applied Biosystems) and an ABI Prism 310 or 3100 genetic analyzer.

RESULTS

Selection of the 3R mutation by WT epitope-specific CD8⁺ T cells in individuals infected with WT virus. We investigated 12 HIV-1-infected HLA-A*24:02⁺ individuals who could be monitored from the early to the chronic phases of their infections. We first analyzed the sequence of the Gag28 epitope at an early phase in the 12 HIV-1-infected HLA-A*24:02⁺ individuals. The WT sequence of the Gag28 epitope was detected in 4 of these individuals, whereas 3R was found in the other 8, suggesting that the former and the latter individuals had been infected with WT and 3R viruses, respectively (Table 1). This is consistent with a previous finding that the 3R mutant is found in approximately 70% of HIV-1-infected HLA-A*24:02⁺ individuals (30). We investigated the elicitation of Gag28-specific CD8⁺ T cells in the individuals infected with WT virus. PBMCs from these individuals at early and chronic phases were stimulated with WT or 3R peptide and then cultured for 2 weeks. The frequency of Gag28-specific CD8⁺ T cells among the cultured cells was measured by performing the ICC assay using WT and 3R peptides. Gag28-specific CD8⁺ T cells were detected at the early phase in 3 of the 4 individuals when the PBMCs were stimulated with WT peptide (Table 2). In 2 individuals, i.e., KI-092 and KI-161, Gag28-specific CD8⁺ T cells were much more WT specific than 3R mutant specific, whereas in KI-158 they recognized both peptides, but especially the WT peptide (Fig. 1). On the other hand, cross-reactive CD8⁺ T cells were induced in KI-092 and KI-161 when their PBMCs had been stimulated with 3R peptide, although the frequency of cross-reactive CD8⁺ T cells induced by stimulation with 3R peptide was lower than that of WT-specific cells induced by stimulation with WT peptide. The 3R peptide failed to induce Gag28-specific CD8⁺ T cells in PBMCs from KI-158. Thus, WT-specific CD8⁺ T cells were predominantly elicited at an early phase in the individuals infected with WT virus, although a small but significant number of cross-reactive T cells were also elicited in them.

To clarify the specificity of Gag28-specific CD8⁺ T cells at the early phase in KI-092 and KI-161, we generated Gag28-specific CTL clones by stimulating early-phase PBMCs from KI-092 and

TABLE 1 Sequence at Gag30 in 12 HLA-A*24:02⁺ individuals with an early-phase HIV-1 infection

Patient ID ^a	Sampling date (mo/day/yr)	Gag30 sequence	Method
KI-091	12/13/2000	3R	Cloning
	12/27/2000	3R	Direct
	1/7/2002	3R	Direct
	7/9/2003	3R	Cloning
	9/29/2004	3R	Cloning
KI-092	8/4/2005	3R	Cloning
	1/22/2001	WT	Cloning
	11/21/2001	WT	Cloning
	12/10/2002	WT/3R	Cloning
KI-102	8/14/2003	3R	Cloning
	5/11/2001	WT	Direct
	7/5/2004	WT	Direct
KI-126	3/28/2005	WT	Direct
	7/19/2001	3R	Direct
	1/18/2002	3R	Direct
	11/15/2004	3R	Direct
KI-134	9/12/2005	3R	Direct
	10/25/2001	3R	Direct
	6/30/2004	3R	Direct
KI-136	10/29/2001	3R	Direct
	7/10/2003	3R	Direct
KI-140	11/08/2001	3R	Direct
KI-151	5/2/2001	3R	Direct
	8/28/2003	3R	Direct
KI-154	4/12/2002	3R	Direct
KI-158	6/14/2002	WT	Direct
	10/11/2002	WT	Direct
	8/25/2003	WT	Direct
	11/14/2003	WT/3R	Direct
	2/23/2004	3R/WT	Direct
	11/1/2004	3R	Direct
	4/4/2005	3R	Direct
	2/15/2002	WT	Direct
KI-161	9/12/2002	WT	Direct
	3/4/2003	WT	Direct
	9/30/2003	WT/3R	Direct
	5/6/2004	3R	Direct
	1/27/2005	3R	Direct
	6/16/2005	3R	Cloning
KI-163	8/30/2002	3R	Direct
	9/27/2004	3R	Direct

^a ID, identifier.

KI-161 with the WT peptide. The CTL clones from KI-092 showed a much greater ability to kill cells prepulsed with WT peptide than to kill those prepulsed with the 3R peptide (Fig. 2A), suggesting that they were WT-specific CTLs. To further clarify the specificity of these T cell clones, we investigated the binding affinity of the clones for WT peptide-binding HLA-A*24:02 tetramer (WT tetramer) and 3R peptide-binding HLA-A*24:02 tetramer (3R tetramer). These clones exhibited much greater binding ability to the WT tetramer than to the 3R tetramer (Fig. 2B). These results together indicate that these were WT-specific CTL clones. We further analyzed the abilities of these clones to recognize HIV-1-infected cells. These CTL clones effectively killed WT-virus-infected cells, but not the 3R virus-infected cells (Fig. 2C), and showed the ability to suppress the replication of WT virus, but not to suppress that of the 3R virus (Fig. 2D). WT-specific CD8⁺ T cell

TABLE 2 Responses of CD8⁺ T cells from individuals infected with WT virus to WT or 3R peptide

Patient ID	Virus sequence [mo/day/yr (type)]		PBMC sampling date (mo/day/yr)	PBMCs cultured with:	% IFN- γ -producing cells specific for each peptide among CD8 ⁺ T cells ^a		
	Early phase	Chronic phase			Without	WT	3R
KI-092	1/22/2001 (WT)	8/14/2003 (3R)	5/24/2001	WT	0.2	34.4	13.7
				3R	0.1	12.1	16.8
			2/3/2003	WT	0.2	5.8	4.2
KI-102	5/11/2001 (WT)	3/28/2005 (WT)	7/11/2001	3R	0.6	0.3	0.3
				WT	1.0	0.6	1.1
			7/5/2004	3R	1.1	1.5	2.0
KI-158	6/14/2002 (WT)	4/4/2005 (3R)	10/11/2002	WT	0.2	28.7	9.3
				3R	0.6	0.7	0.6
			4/4/2005	WT	1.4	19.3	24.6
KI-161	2/15/2002 (WT)	6/16/2005 (3R)	7/26/2002	3R	0.1	0.5	0.4
				WT	0.3	23.3	23.8
			5/6/2004	3R	0.4	18.8	20.9
			WT	0.0	74.5	8.0	
			3R	0.2	55.1	41.8	
			WT	0.1	21.4	4.9	
			3R	0.2	42.5	43.9	

^a Without, without peptide. Boldface, positive IFN- γ -producing response.

clones established from early-phase PBMCs of KI-161 also showed a similar ability to kill WT virus-infected and 3R virus-infected cells (Fig. 3). In these individuals, the 3R mutant virus became dominant 1 to 2 years after the early phase (Table 1). Taken together, these findings suggest that the 3R mutation was selected by WT-specific CTLs.

The 3R virus was not detected by approximately 4 years postinfection in KI-102, who had been infected with the WT virus (Table 1). This individual did not have Gag28-specific CD8⁺ T cells at an early phase of the HIV-1 infection (Fig. 1). Interestingly, only WT-specific CD8⁺ T cells were induced from PBMCs of this patient 2.5 year later. Thus, WT-specific CD8⁺ T cells did not select 3R within about 2 years after the WT-specific CD8⁺ T cells had been elicited in the patient.

Cross-reactive CD8⁺ T cells in individuals who had been infected with WT virus and had selected 3R virus. We investigated whether the 3R-specific or cross-reactive CD8⁺ T cells were elicited after the 3R mutant had been selected in individuals who had been infected with the WT virus. In KI-158, no Gag28-specific CD8⁺ T cells were induced from early-phase PBMCs stimulated with the 3R peptide, whereas cross-reactive CD8⁺ T cells were induced from chronic-phase PBMCs stimulated with WT peptide or 3R peptide (Fig. 1). In KI-161, Gag28-specific CD8⁺ T cells recognizing WT peptide more than the 3R peptide were induced from early-phase PBMCs stimulated with WT peptide or the 3R peptide, whereas cross-reactive CD8⁺ T cells were predominantly induced from chronic-phase PBMCs stimulated with the 3R peptide (Fig. 1). These results indicate that cross-reactive CD8⁺ T cells became dominant in the Gag28-specific CD8⁺ T cell population after the emergence of the 3R virus in these 2 individuals.

To investigate the function of these cross-reactive CD8⁺ T cells, we generated Gag28-specific CTL clones from PBMCs at a chronic phase in KI-161 by stimulating them with the 3R peptide. The CTL clones evenly recognized both WT and the 3R peptides (Fig. 3A) and showed the same binding affinity to the 2 tetramers (Fig. 3B). These results suggest that the two peptides had the same

binding affinity for HLA-A*24:02. They effectively killed WT-virus-infected cells and weakly killed the 3R virus-infected cells (Fig. 3C), whereas they suppressed the replication of the WT virus but not that of the 3R virus (Fig. 3D). These results indicate that these cross-reactive CTLs contributed to the selection of the 3R virus. In addition, the results strongly suggest weak presentation of the 3R peptide in the cells infected with 3R virus, because the cross-reactive CTL clones had TCR with the same binding affinity for both HLA-A*24:02-WT peptide and HLA-A*24:02-3R peptide complexes and because WT and 3R peptides had the same binding affinity for HLA-A*24:02. This reduced presentation may have affected the control of 3R virus by the cross-reactive CTLs.

Gag28-specific T cell repertoire in an individual infected with WT virus. The results in Fig. 1 suggest that both WT-specific and cross-reactive CD8⁺ T cells were elicited at an early phase of HIV-1 infection in 3 individuals infected with WT virus (KI-092, KI-158, and KI-161). To characterize Gag28-specific CTLs elicited at that time, we established Gag28-specific CTL clones from PBMCs at an early phase in KI-161 by stimulating them with the WT peptide. We found 3 types of CTL clones among the 8 clones analyzed. As shown in Fig. 3A, 3 clones effectively recognized the WT peptide but not the 3R peptide (WT specific), 3 clones recognized the WT peptide more than the 3R peptide (WT dominant), and 2 clones evenly recognized both peptides (cross-reactive). We next investigated the binding affinity of TCRs on these clones to WT tetramer and 3R tetramer. The results confirmed the specificity of these 3 types of CTL clones (Fig. 3B). These results together indicate that KI-161 had a multiple T cell repertoire for the Gag28 epitope before the 3R virus had been selected.

Next, we analyzed the abilities of these T cell clones to kill HIV-1-infected cells. The WT-specific and WT-dominant CTL clones effectively killed the target cells infected with WT virus but failed to kill those infected with the 3R virus (Fig. 3C, left and right graphs under early phase). On the other hand, cross-reactive CTL clones weakly killed the target cells infected with the 3R virus and effectively killed those infected with the WT virus (Fig. 3C, middle




FIG 1 Gag28-specific CD8⁺ T cells from individuals infected with WT virus at early and chronic phases. Gag28-specific CD8⁺ T cells were induced by stimulating PBMCs from early and chronic phases in 4 WT-virus-infected HLA-A*24:02⁺ individuals with WT or 3R peptide. The responses of these bulk-cultured cells to C1R-A2402 cells prepulsed with WT or 3R peptide at concentrations of 0.1 to 1,000 nM were analyzed by using the ICC assay.

graphs under early phase). Then, we analyzed the abilities of these CTL clones to suppress HIV-1 replication. Both WT-specific and cross-reactive CTL clones effectively suppressed the replication of the WT virus, whereas WT-specific and cross-reactive CTL clones exhibited no and weak ability, respectively, to suppress that of the 3R virus (Fig. 3D). These results indicate that WT-specific and cross-reactive CTLs could suppress the replication of the WT virus

but that the former CTLs could not suppress the 3R virus *in vivo*. The latter CTLs may weakly suppress 3R virus *in vivo*. Interestingly, the WT-dominant CTL clones exhibited much weaker ability to suppress the replication of WT virus than did the WT-specific and cross-reactive CTLs (Fig. 3D), although no difference in killing activity against WT-virus-infected cells was found among these 3 CTL clones. Overall, KI-161 had a multiple Gag28-




FIG 2 Antiviral activity of Gag28-specific CTL clones generated from early-phase PBMCs from patient KI-092, infected with WT virus. Gag28-specific CTL clones were generated from early-phase PBMCs from KI-092 by stimulating them with WT peptide. The activities of 3 CTL clones ($n = 3$) were analyzed. (A) Cytotoxic activity toward 721.221-CD4-A2402 cells prepulsed with the WT or 3R peptide at concentrations of 1 to 1,000 nM. The cytotoxic activity was measured at an E:T ratio of 1:1. (B) Binding affinity to WT and 3R tetramers at concentrations of 1 to 100 nM. The MFI values of the T cell clones are shown. (C) Cytotoxic activity against 721.221-CD4-A2402 cells infected with NL-432gag^{SF2} (WT virus) or NL-432gag^{SF2}-3R (3R virus). WT-virus-infected (49.1% of total cells were p24 Ag⁺) and 3R virus-infected (48.6% of total cells were p24 Ag⁺) cells were used as target cells. The cytotoxic activity was measured at E:T ratios of 0.5:1, 1:1, and 2:1. (D) Abilities of the clones to suppress the replication of WT or 3R viruses. The ability was tested at different E:T ratios. The error bars indicate standard deviations.

specific CTL repertoire at an early phase of HIV-1 infection, but only 2 types of Gag28-specific CTLs, which were the majority among the Gag28-specific CTLs, contributed to the suppression of WT virus replication.

Cross-reactive CD8⁺ T cells and 3R-specific CD8⁺ T cells in individuals who were infected with 3R virus. Next, we analyzed the elicitation of Gag28-specific CD8⁺ T cells in 5 individuals infected with the 3R virus. Gag28-specific CD8⁺ T cells were detected at both early and chronic phases in 3 individuals, whereas they were found at only the chronic phase in the other 2 (Table 3). Cross-reactive CD8⁺ T cells were induced by stimulating KI-091 PBMCs from both early and chronic phases, not only with 3R peptide, but also with WT peptide. To characterize Gag28-specific CD8⁺ T cells in KI-091, we generated Gag28-specific CTL clones from PBMCs at a chronic phase in KI-091 by stimulating them with 3R peptide. We investigated the recognition of 3 CTL clones for WT and 3R peptides. These CTL clones evenly recognized both peptides (Fig. 4A) and revealed the same binding affinity for the 2 tetramers (Fig. 4B), indicating that they were cross-reactive CTLs. They moderately killed target cells infected with either WT or 3R

virus (Fig. 4C) but did not suppress the replication of the WT and 3R viruses (Fig. 4D). Thus, Gag28-specific CD8⁺ T cells elicited in KI-091 had no ability to suppress the replication of WT and 3R viruses. Further analysis of 13 other clones revealed similar characteristics (data not shown), supporting the data indicating that cross-reactive CTLs were predominantly elicited in KI-091.

In the chronic phase, KI-091 had cross-reactive CD8⁺ T cells, whereas 3R-specific CD8⁺ T cells were found in 4 other individuals (Table 3). To characterize these 3R-specific CD8⁺ T cells, we generated 3R-specific CTL clones from KI-163 PBMCs at the chronic phase by stimulating them with 3R peptide. All 3 clones recognized the 3R peptide much more effectively than the WT peptide (Fig. 4A). These CTL clones bound to 3R tetramer, but not to WT tetramer (Fig. 4B), indicating that these CTL clones carried a 3R-specific TCR. In addition, we analyzed the abilities of these CTL clones to recognize virus-infected cells and found that they effectively killed target cells infected with 3R virus, but not those infected with WT virus (Fig. 4C). However, they failed to suppress the replication of either 3R or WT virus (Fig. 4D). These results indicate that Gag28-specific CD8⁺ T cells elicited in all individuals infected with 3R virus had no ability to suppress the replication of WT or 3R virus. Thus, Gag28-specific CD8⁺ T cells seem to have failed to control the 3R virus, although they were elicited in individuals infected with the 3R virus.

High accumulation of the 3R variant in the Japanese population. The results described above strongly suggest that WT-specific and cross-reactive CD8⁺ T cells selected the 3R mutation in the individuals infected with the WT virus and that 3R-specific and cross-reactive CD8⁺ T cells failed to control the 3R virus in the individuals infected with it. Therefore, we assume that this 3R mutation has accumulated in the HLA-A*24:02⁺ individuals. In addition, since HLA-A*24:02 is found in approximately 70% of Japanese, we speculate that the mutation has accumulated to high levels in the Japanese population.

A previous study analyzed the frequency of 3R in only 32 HLA-A*24:02⁺ and 26 HLA-A*24:02⁻ individuals chronically infected with HIV-1 and showed that the frequency of 3R was significantly higher in HLA-A*24:02⁺ individuals than in the HLA-A*24:02⁻ individuals (30). To confirm the association of this mutation with HLA-A*24:02, we analyzed a large number of chronically HIV-1-infected nonhemophiliac individuals (220 HLA-A*24:02⁺ and 154 HLA-A*24:02⁻ individuals) recruited from April 2008 to March 2011 (2008 to 2011 cohort). The results confirmed that the frequency of 3R was significantly higher in HLA-A*24:02⁺ individuals than in the HLA-A*24:02⁻ individuals ($P < 0.0005$) (Fig. 5). Since 3R was found in 74.7% of the HLA-A*24:02⁻ individuals in this cohort, we speculate that the mutation has been accumulating in the Japanese population. Therefore, we analyzed HIV-1-infected nonhemophiliac Japanese individuals who had been recruited from 1996 to 2002 (1996 to 2002 cohort), as well as Japanese hemophiliacs who had been infected around 1983 (hemophiliac cohort), and then compared them to the 2008 to 2011 cohort (Fig. 5). The association of this mutation with HLA-A*24:02 was also found in both the 1996 to 2002 cohort and the hemophiliac cohort ($P < 0.01$ and $P = 7.4 \times 10^{-7}$, respectively). The frequency of this mutation in HLA-A*24:02⁻ individuals significantly increased from 0% in the hemophiliac cohort to 50.0% in the 1996 to 2002 cohort ($P = 0.0084$) and to 74.7% in the 2008 to 2011 cohort ($P = 2.6 \times 10^{-7}$). These results indicate that the 3R mutation was strongly selected by Gag28-specific CTLs and has




FIG 3 Antiviral activities of Gag28-specific CTL clones generated from PBMCs of patient KI-161, infected with WT virus. Gag28-specific CTL clones were generated from early-phase and chronic-phase PBMCs isolated from KI-161 after stimulating them with the WT and 3R peptides, respectively. Three types of Gag28-36-specific CTL clones, i.e., WT specific (left), cross-reactive (middle), and WT dominant (right), were generated from the early-phase PBMCs. (A) Cytotoxic activity against 721.221-CD4-A2402 cells prepulsed with the WT or 3R peptide at concentrations of 1 to 1,000 nM. The cytotoxic activity was measured at an E:T ratio of 1:1. (B) Binding affinity toward WT and 3R tetramers at concentrations of 1 to 100 nM. The MFIs of the T cell clones are shown. (C) Cytotoxic activity against 721.221-CD4-A2402 cells infected with WT virus or 3R virus. WT-virus-infected (49.0% of total cells were p24 Ag⁺) and 3R-virus-infected (50.0% of total cells were p24 Ag⁺) cells were used as target cells. The cytotoxic activity was measured at E:T ratios of 0.5:1, 1:1, and 2:1. (D) Abilities of the clones to suppress the replication of WT or 3R virus. The ability was tested at different E:T ratios. n, number of clones tested. The error bars indicate standard deviations.

been accumulating during the past 30 years in the Japanese population.

It is well known that some escape mutations affect replication capacity and that HIV-1 containing such mutations reverts to WT

in individuals not carrying HLA class I restriction alleles (23, 32). We previously showed that the 3R mutation does not affect replication capacity when 2 T cell lines are used in an assay measuring it (46). Since a different effect of mutations on replication capacity

TABLE 3 Responses of CD8⁺ T cells from individuals infected with 3R virus to WT or 3R peptide

Patient ID	Virus sequence [mo/day/yr (type)]		PBMC sampling date (mo/day/yr)	PBMCs cultured with:	% IFN- γ -producing cells specific for each peptide among CD8 ⁺ T cells ^a		
	Early phase	Chronic phase			Without	WT	3R
KI-091	12/13/2000 (3R)	8/4/2005 (3R)	12/13/2000	WT	0.2	74.6	71.2
				3R	0.3	55.4	71.9
			9/29/2004	WT	0.2	77.7	65.5
KI-134	10/25/2001 (3R)	6/30/2004 (3R)	10/25/2001	3R	0.2	61.1	69.3
				WT	0.4	0.6	0.8
			1/21/2004	3R	1.0	1.1	5.7
KI-136	10/29/2001 (3R)	7/10/2003 (3R)	10/29/2001	WT	0.8	1.0	0.7
				3R	0.7	0.6	2.0
			5/15/2003	WT	0.1	0.4	0.2
KI-151	2/15/2002 (3R)	6/16/2005 (3R)	11/21/2001	3R	0.1	0.2	0.2
				WT	0.4	0.8	0.4
			7/28/2004	3R	0.1	0.2	24.8
KI-163	8/30/2002 (3R)	9/27/2004 (3R)	8/30/2002	WT	0.3	0.7	0.8
				3R	0.7	0.6	10.8
			8/29/2005	WT	0.4	0.7	1.3
			3R	0.1	0.1	44.5	
			WT	0.2	0.3	0.2	
			3R	0.2	0.4	0.2	
			WT	0.3	0.5	0.2	
			3R	0.4	0.6	6.9	

^a Without, without peptide. Boldface, positive IFN- γ -producing response.

between cell lines and CD4⁺ T cells from a healthy individual is known (23), we measured the replication capacity of the 3R virus by using CD4⁺ T cells from a healthy individual. The results confirm that this mutation did not affect the replication capacity (Fig. 6), suggesting that the 3R mutant could not revert in HLA-A*24:02⁻ individuals.

DISCUSSION

It is known that CTLs recognizing escape mutants are elicited after the escape mutant had been selected by WT epitope-specific CTLs (2, 4, 12, 15, 33, 39) or in new escape mutant virus-infected hosts having the same restricted HLA allele (15). However, since the CTLs recognizing escape mutants have been not well analyzed, the role of these CTLs in the control of HIV-1 infections remains unclear. In the present study, we investigated 2 groups, HLA-A*24:02⁺ individuals infected with WT virus and those infected with 3R escape mutant virus. We found that both WT-specific and cross-reactive CD8⁺ T cells were elicited in individuals infected with WT virus. Interestingly, cross-reactive T cells had been elicited before the emergence of the 3R escape mutant virus, though a similar finding was made in previous studies that analyzed other epitope-specific CTLs (18, 25, 26, 34). The present study shows that WT-specific CD8⁺ T cells were predominantly elicited in an early phase of the infection and that the number of cross-reactive CD8⁺ T cells increased in the chronic phase. The CTL clones from early and chronic phases in KI-161 showed similar abilities to kill WT virus-infected or 3R virus-infected cells and activities to suppress both viruses, suggesting that cross-reactive CD8⁺ T cells elicited at the early phase were expanded via antigen presentation by 3R virus-infected cells at the chronic phase.

WT-specific and cross-reactive CTL clones from KI-092 and KI-161 at an early phase of the infection effectively killed WT-virus-infected cells and suppressed the replication of the WT vi-

rus, whereas they exhibited no and weak ability, respectively, to suppress that of the 3R virus. Cross-reactive CTL clones had the same ability to suppress the replication of WT virus as did the WT-specific CTL clones. These results strongly suggest that both CTLs selected the 3R virus in these individuals infected with the WT virus. The 3R virus was not selected within at least 1 year after Gag28-specific CTLs had been detected in the individuals infected with the WT virus. This finding indicates that the 3R mutation was more slowly selected by these CTLs than escape mutants selected at an acute phase of the infection (16, 19, 34, 44, 45). On the other hand, a previous study suggested that acute accumulation of mutations in this epitope occurs after an HIV-1 infection (6). However, the data shown in that study concerned mutations contained at position 1 of the epitope. In addition, those data may have included cases in which the individuals had been infected with the 3R mutant virus, because it may be assumed that 3R virus had accumulated in the cohorts analyzed. Cross-reactive CTL clones established from PBMCs at both early and chronic phases of KI-161 killed 3R virus-infected cells, though the killing activity against the 3R virus-infected cells was weaker than that against the WT virus-infected cells. These CTL clones weakly suppressed the replication of the 3R virus (Fig. 3C). This weak ability to suppress it might have delayed the emergence of the 3R mutation in these patients.

WT-specific CTLs were not induced by stimulation of early- or chronic-phase PBMCs from the 5 individuals in which the 3R mutation had been detected at the early phase with WT peptides. This finding supports the possibility that these individuals had been infected with the 3R virus. Only KI-091 had cross-reactive T cells at early and chronic phases of the infection. All CTL clones established from this patient had cross-reactivity, implying that the patient had been infected with WT virus and that 3R had been selected at an early phase. However, WT-specific CTL clones were not established from this patient. In addition, the cross-reactive